TGD001 Treatment in Thrombotic Microangiopathies

This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.

NCT Number	NCT07459114
Lead Sponsor	TargED Biopharmaceuticals B.V.
Conditions	Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Enrollment	70 participants
Start Date	2026-05-31
Primary Completion	2028-05-31 (estimated)
Study Completion	2028-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-09